KHIDI Regenerative Medicine R&D (seed)
Funds Korean and partner teams advancing cell and gene therapies and tissue engineering in frontier healthcare innovation.
KHIDI identifies regenerative medicine as one of three priority next-generation healthcare technology areas within its Health Industry R&D support mandate, alongside innovative new drugs and medical devices. The regenerative medicine programme funds R&D in cell therapy, gene therapy, and tissue engineering — the three primary modalities of the field — with the goal of advancing Korea's position in…
Funds Korean R&D in cell therapy, gene therapy, and tissue engineering as a priority next-generation healthcare technology area within KHIDI's annual health industry support mandate.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see the timeline